Psychology Wiki

Mild androgen insensitivity syndrome

34,117pages on
this wiki
Revision as of 00:04, October 4, 2013 by Dr Joe Kiff (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

Mild androgen insensitivity syndrome
Classification and external resources
AIS results when the function of the androgen receptor (AR) is impaired. The AR protein (pictured) mediates the effects of androgens in the human body.
ICD-10 E3450
ICD-9 259.50
OMIM 312300 300068
DiseasesDB 29662 12975
eMedicine ped/2222
MeSH D013734
GeneReviews Template:Citation/make link

Mild androgen insensitivity syndrome (MAIS) is a condition that results in a mild impairment of the cell's ability to respond to androgens.[1][2][3] The degree of impairment is sufficient to impair spermatogenesis and / or the development of secondary sexual characteristics at puberty in males, but does not affect genital differentiation or development. Female genital and sexual development is not significantly affected by the insensitivity to androgens[3][4]; as such, MAIS is only diagnosed in males.[1] The clinical phenotype associated with MAIS is a normal male habitus with mild spermatogenic defect and / or reduced secondary terminal hair.[1][5][6][7][8][9]

MAIS is one of three types of androgen insensitivity syndrome, which is divided into three categories that are differentiated by the degree of genital masculinization: complete androgen insensitivity syndrome (CAIS) is indicated when the external genitalia is that of a normal female, mild androgen insensitivity syndrome (MAIS) is indicated when the external genitalia is that of a normal male, and partial androgen insensitivity syndrome (PAIS) is indicated when the external genitalia is partially, but not fully masculinized.[1][2][5][6][7][10][11][12][13]

Androgen insensitivity syndrome is the largest single entity that leads to 46,XY undermasculinization.[14]

Signs and symptomsEdit

File:Mild androgen insensitivity syndrome.jpg
Mild androgen insensitivity syndrome (MAIS) presenting with a mild impairment of virilization in a 23-year-old man.[15]

Individuals with mild (or minimal) androgen insensitivity syndrome (grade 1 on the Quigley scale) are born phenotypically male, with fully masculinized genitalia; this category of androgen insensitivity is diagnosed when the degree of androgen insensitivity in an individual with a 46,XY karyotype is great enough to impair virilization or spermatogenesis, but is not great enough to impair normal male genital development.[1][5][6][9] MAIS is the mildest and least known form of androgen insensitivity syndrome.[5][16]

The existence of a variant of androgen insensitivity that solely affected spermatogenesis was theoretical at first.[17] Cases of phenotypically normal males with isolated spermatogenic defect due to AR mutation were first detected as the result of male infertility evaluations.[1][13][18][19] Until then, early evidence in support of the existence of MAIS was limited to cases involving a mild defect in virilization,[15][20] although some of these early cases made allowances for some degree of impairment of genital masculinization, such as hypospadias or micropenis.[21][22][23] It is estimated that 2-3% of infertile men have AR gene mutations.[6]

Examples of MAIS phenotypes include isolated infertility (oligospermia or azoospermia),[5][7] mild gynecomastia in young adulthood, decreased secondary terminal hair, high pitched voice, or minor hypospadias repair in childhood.[1][24] The external male genitalia (penis, scrotum, and urethra) are otherwise normal in individuals with MAIS.[1][5][6][9] Internal genitalia, including Wolffian structures (the epididymides, vasa deferentia, and seminal vesicles) and the prostate, is also normal, although the bitesticular volume of infertile men (both with and without MAIS) is diminished [6]; male infertility is associated with reduced bitesticular volume, varicocele, retractile testes, low ejaculate volume, male accessory gland infections (MAGI), and mumps orchitis.[6] The incidence of these features in infertile men with MAIS is similar to that of infertile men without MAIS.[6] MAIS is not associated with Müllerian remnants.

Kennedy DiseaseEdit

Kennedy disease, also known as spinal and bulbar muscular atrophy (SBMA), is a severe neurodegenerative syndrome that is associated with a particular mutation of the androgen receptor's polyglutamine tract called a trinucleotide repeat expansion.[25][26] SBMA results when the length of the polyglutamine tract exceeds 40 repetitions.[27]

Although technically a variant of MAIS, SBMA's presentation is not typical of androgen insensitivity; symptoms do not occur until adulthood and include neuromuscular defects as well as signs of androgen inaction.[25] Neuromuscular symptoms include progressive proximal muscle weakness, atrophy, and fasciculations. Symptoms of androgen insensitivity experienced by men with SBMA are also progressive [25] and include testicular atrophy, severe oligospermia or azoospermia, gynecomastia, and feminized skin changes [28] despite elevated androgen levels.[1] Disease onset, which usually affects the proximal musculature first, occurs in the third to fifth decades of life, and is often preceded by muscular cramps on exertion, tremor of the hands, and elevated muscle creatine kinase.[29] SBMA is often misdiagnosed as amyotrophic lateral sclerosis (ALS) (also known as Lou Gehrig's disease).[26]

The symptoms of SBMA are thought to be brought about by two simultaneous pathways involving the toxic misfolding of proteins and loss of AR functionality.[1] The polyglutamine tract in affected pedigrees tends to increase in length over generations, a phenomenon known as "anticipation",[30] leading to an increase in the severity of the disease as well as a decrease in the age of onset for each subsequent generation of a family affected by SBMA.[25]


File:Histopathology of androgen insensitivity.jpg
Histopathology of testicular tissue showing immature germ cells and spermatagonia with decreased tubular diameter. Scattered groups of Leydig cells appearing immature.[31]

All forms of androgen insensitivity are associated with infertility, though exceptions have been reported for both the mild and partial forms.[4][5][7][32][33][34] Lifespan is not thought to be affected by AIS.[1]

Trinucleotide Satellite Lengths and AR Transcriptional ActivityEdit

Main article: Androgen insensitivity syndrome#Genetics

The androgen receptor gene contains two polymorphic trinucleotide microsatellites in exon 1.[2] The first microsatellite (nearest the 5' end) contains 8 [35] to 60 [26][29] repetitions of the glutamine codon "CAG" and is thus known as the polyglutamine tract.[3] The second microsatellite contains 4 [36] to 31 [37] repetitions of the glycine codon "GGC" and is known as the polyglycine tract.[38] The average number of repetitions varies by ethnicity, with Caucasians exhibiting an average of 21 CAG repeats, and Blacks 18.[39] Disease states are associated with extremes in polyglutamine tract length; prostate cancer,[25] hepatocellular carcinoma,[40] and mental retardation [35] are associated with too few repetitions, while spinal and bulbar muscular atrophy (SBMA) is associated with a CAG repetition length of 40 or more.[27] Some studies indicate that the length of the polyglutamine tract is inversely correlated with transcriptional activity in the AR protein, and that longer polyglutamine tracts may be associated with infertility [41][42][43] and undermasculinized genitalia.[44] However, other studies have indicated that no such correlation exists.[45][46][47][48][49][50] A comprehensive meta-analysis of the subject published in 2007 supports the existence of the correlation, and concluded that these discrepancies could be resolved when sample size and study design are taken into account.[11] Longer polyglycine tract lengths have also been associated with genital masculinization defects in some,[51][52] but not all,[53] studies.


Main article: Androgen insensitivity syndrome

MAIS is only diagnosed in normal phenotypic males, and is not typically investigated except in cases of male infertility.[18] MAIS has a mild presentation that often goes unnoticed and untreated [15]; even with semenological, clinical and laboratory data, it can be difficult to distinguish between men with and without MAIS, and thus a diagnosis of MAIS is not usually made without confirmation of an AR gene mutation.[5] The androgen sensitivity index (ASI), defined as the product of luteinizing hormone (LH) and testosterone (T), is frequently raised in individuals with all forms of AIS, including MAIS, although many individuals with MAIS have an ASI in the normal range.[5] Testosterone levels may be elevated despite normal levels of luteinizing hormone.[15][20][24] Conversion of testosterone (T) to dihydrotestosterone (DHT) may be impaired, although to a lesser extent than is seen in 5α-reductase deficiency.[3] A high ASI in a normal phenotypic male,[45] especially when combined with azoospermia or oligospermia,[5][7] decreased secondary terminal hair,[26] and/or impaired conversion of T to DHT, [3] can be indicative of MAIS, and may warrant genetic testing.


Due to its mild presentation, MAIS often goes unnoticed and untreated.[15] Management of MAIS is currently limited to symptomatic management; methods to correct a malfunctioning androgen receptor protein that result from an AR gene mutation are not currently available. Treatment includes surgical correction of mild gynecomastia, minor hypospadias repair, and testosterone supplementation.[1][15][54] Supraphysiological doses of testosterone have been shown to correct diminished secondary sexual characteristics in men with MAIS,[15] as well as to reverse infertility due to low sperm count.[54][55] As is the case with PAIS, men with MAIS will experience side effects from androgen therapy (such as the suppression of the hypothalamic-pituitary-gonadal axis) at a higher dosage than unaffected men. Careful monitoring is required to ensure the safety and efficacy of treatment.[15][56][57] Regular breast [56] and prostate [58] examinations may be necessary due to comorbid association with breast and prostate cancers.


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 Hughes IA, Deeb A (December 2006). Androgen resistance. Best Pract. Res. Clin. Endocrinol. Metab. 20 (4): 577–98.
  2. 2.0 2.1 2.2 Galani A, Kitsiou-Tzeli S, Sofokleous C, Kanavakis E, Kalpini-Mavrou A (2008). Androgen insensitivity syndrome: clinical features and molecular defects. Hormones (Athens) 7 (3): 217–29.
  3. 3.0 3.1 3.2 3.3 3.4 Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM, French FS (June 1995). Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr. Rev. 16 (3): 271–321.
  4. 4.0 4.1 Giwercman YL, Nordenskjöld A, Ritzén EM, Nilsson KO, Ivarsson SA, Grandell U, Wedell A (June 2002). An androgen receptor gene mutation (E653K) in a family with congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency as well as in partial androgen insensitivity. J. Clin. Endocrinol. Metab. 87 (6): 2623–8.
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 5.8 5.9 Zuccarello D, Ferlin A, Vinanzi C, Prana E, Garolla A, Callewaert L, Claessens F, Brinkmann AO, Foresta C (April 2008). Detailed functional studies on androgen receptor mild mutations demonstrate their association with male infertility. Clin. Endocrinol. (Oxf) 68 (4): 580–8.
  6. 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 Ferlin A, Vinanzi C, Garolla A, Selice R, Zuccarello D, Cazzadore C, Foresta C (November 2006). Male infertility and androgen receptor gene mutations: clinical features and identification of seven novel mutations. Clin. Endocrinol. (Oxf) 65 (5): 606–10.
  7. 7.0 7.1 7.2 7.3 7.4 Stouffs K, Tournaye H, Liebaers I, Lissens W (2009). Male infertility and the involvement of the X chromosome. Hum. Reprod. Update 15 (6): 623–37.
  8. Giwercman YL, Nikoshkov A, Byström B, Pousette A, Arver S, Wedell A (June 2001). A novel mutation (N233K) in the transactivating domain and the N756S mutation in the ligand binding domain of the androgen receptor gene are associated with male infertility. Clin. Endocrinol. (Oxf) 54 (6): 827–34.
  9. 9.0 9.1 9.2 Lund A, Juvonen V, Lähdetie J, Aittomäki K, Tapanainen JS, Savontaus ML (June 2003). A novel sequence variation in the transactivation regulating domain of the androgen receptor in two infertile Finnish men. Fertil. Steril. 79 Suppl 3: 1647–8.
  10. Ozülker T, Ozpaçaci T, Ozülker F, Ozekici U, Bilgiç R, Mert M (January 2010). Incidental detection of Sertoli-Leydig cell tumor by FDG PET/CT imaging in a patient with androgen insensitivity syndrome. Ann Nucl Med 24 (1): 35–9.
  11. 11.0 11.1 Davis-Dao CA, Tuazon ED, Sokol RZ, Cortessis VK (November 2007). Male infertility and variation in CAG repeat length in the androgen receptor gene: a meta-analysis. J. Clin. Endocrinol. Metab. 92 (11): 4319–26.
  12. Kawate H, Wu Y, Ohnaka K, Tao RH, Nakamura K, Okabe T, Yanase T, Nawata H, Takayanagi R (November 2005). Impaired nuclear translocation, nuclear matrix targeting, and intranuclear mobility of mutant androgen receptors carrying amino acid substitutions in the deoxyribonucleic acid-binding domain derived from androgen insensitivity syndrome patients. J. Clin. Endocrinol. Metab. 90 (11): 6162–9.
  13. 13.0 13.1 Gottlieb B, Lombroso R, Beitel LK, Trifiro MA (January 2005). Molecular pathology of the androgen receptor in male (in)fertility. Reprod. Biomed. Online 10 (1): 42–8.
  14. Ahmed SF, Cheng A, Hughes IA (April 1999). Assessment of the gonadotrophin-gonadal axis in androgen insensitivity syndrome. Arch. Dis. Child. 80 (4): 324–9.
  15. 15.0 15.1 15.2 15.3 15.4 15.5 15.6 15.7 Pinsky L, Kaufman M, Killinger DW (January 1989). Impaired spermatogenesis is not an obligate expression of receptor-defective androgen resistance. Am. J. Med. Genet. 32 (1): 100–4.
  16. Wang Q, Ghadessy FJ, Yong EL (September 1998). Analysis of the transactivation domain of the androgen receptor in patients with male infertility. Clin. Genet. 54 (3): 185–92.
  17. Wang Q, Ghadessy FJ, Trounson A, de Kretser D, McLachlan R, Ng SC, Yong EL (December 1998). Azoospermia associated with a mutation in the ligand-binding domain of an androgen receptor displaying normal ligand binding, but defective trans-activation. J. Clin. Endocrinol. Metab. 83 (12): 4303–9.
  18. 18.0 18.1 Oakes MB, Eyvazzadeh AD, Quint E, Smith YR (December 2008). Complete androgen insensitivity syndrome--a review. J Pediatr Adolesc Gynecol 21 (6): 305–10.
  19. Yong EL, Loy CJ, Sim KS (2003). Androgen receptor gene and male infertility. Hum. Reprod. Update 9 (1): 1–7.
  20. 20.0 20.1 Grino PB, Griffin JE, Cushard WG, Wilson JD (April 1988). A mutation of the androgen receptor associated with partial androgen resistance, familial gynecomastia, and fertility. J. Clin. Endocrinol. Metab. 66 (4): 754–61.
  21. Shkolny DL, Beitel LK, Ginsberg J, Pekeles G, Arbour L, Pinsky L, Trifiro MA (February 1999). Discordant measures of androgen-binding kinetics in two mutant androgen receptors causing mild or partial androgen insensitivity, respectively. J. Clin. Endocrinol. Metab. 84 (2): 805–10.
  22. Pinsky L, Kaufman M, Killinger DW, Burko B, Shatz D, Volpé R (September 1984). Human minimal androgen insensitivity with normal dihydrotestosterone-binding capacity in cultured genital skin fibroblasts: evidence for an androgen-selective qualitative abnormality of the receptor. Am. J. Hum. Genet. 36 (5): 965–78.
  23. Tsukada T, Inoue M, Tachibana S, Nakai Y, Takebe H (October 1994). An androgen receptor mutation causing androgen resistance in undervirilized male syndrome. J. Clin. Endocrinol. Metab. 79 (4): 1202–7.
  24. 24.0 24.1 Zenteno JC, Chávez B, Vilchis F, Kofman-Alfaro S (2002). Phenotypic heterogeneity associated with identical mutations in residue 870 of the androgen receptor. Horm. Res. 57 (3-4): 90–3.
  25. 25.0 25.1 25.2 25.3 25.4 Casella R, Maduro MR, Lipshultz LI, Lamb DJ (November 2001). Significance of the polyglutamine tract polymorphism in the androgen receptor. Urology 58 (5): 651–6.
  26. 26.0 26.1 26.2 26.3 Dejager S, Bry-Gauillard H, Bruckert E, Eymard B, Salachas F, LeGuern E, Tardieu S, Chadarevian R, Giral P, Turpin G (August 2002). A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. J. Clin. Endocrinol. Metab. 87 (8): 3893–901.
  27. 27.0 27.1 La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH (July 1991). Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352 (6330): 77–9.
  28. Arbizu T, Santamaría J, Gomez JM, Quílez A, Serra JP (June 1983). A family with adult spinal and bulbar muscular atrophy, X-linked inheritance and associated testicular failure. J. Neurol. Sci. 59 (3): 371–82.
  29. 29.0 29.1 Choong CS, Wilson EM (December 1998). Trinucleotide repeats in the human androgen receptor: a molecular basis for disease. J. Mol. Endocrinol. 21 (3): 235–57.
  30. Biancalana V, Serville F, Pommier J, Julien J, Hanauer A, Mandel JL (July 1992). Moderate instability of the trinucleotide repeat in spino bulbar muscular atrophy. Hum. Mol. Genet. 1 (4): 255–8.
  31. Nichols JL, Bieber EJ, Gell JS (March 2009). Case of sisters with complete androgen insensitivity syndrome and discordant Müllerian remnants. Fertil. Steril. 91 (3): 932.e15–8.
  32. Chu J, Zhang R, Zhao Z, Zou W, Han Y, Qi Q, Zhang H, Wang JC, Tao S, Liu X, Luo Z (January 2002). Male fertility is compatible with an Arg(840)Cys substitution in the AR in a large Chinese family affected with divergent phenotypes of AR insensitivity syndrome. J. Clin. Endocrinol. Metab. 87 (1): 347–51.
  33. Menakaya UA, Aligbe J, Iribhogbe P, Agoreyo F, Okonofua FE (May 2005). Complete androgen insensitivity syndrome with persistent Mullerian derivatives: a case report. J Obstet Gynaecol 25 (4): 403–5.
  34. Giwercman A, Kledal T, Schwartz M, Giwercman YL, Leffers H, Zazzi H, Wedell A, Skakkebaek NE (June 2000). Preserved male fertility despite decreased androgen sensitivity caused by a mutation in the ligand-binding domain of the androgen receptor gene. J. Clin. Endocrinol. Metab. 85 (6): 2253–9.
  35. 35.0 35.1 Kooy RF, Reyniers E, Storm K, Vits L, van Velzen D, de Ruiter PE, Brinkmann AO, de Paepe A, Willems PJ (July 1999). CAG repeat contraction in the androgen receptor gene in three brothers with mental retardation. Am. J. Med. Genet. 85 (3): 209–13.
  36. Audi L, Fernández-Cancio M, Carrascosa A, et al. (April 2010). Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development. J. Clin. Endocrinol. Metab. 95 (4): 1876–88.
  37. Lumbroso R, Beitel LK, Vasiliou DM, Trifiro MA, Pinsky L (November 1997). Codon-usage variants in the polymorphic (GGN)n trinucleotide repeat of the human androgen receptor gene. Hum. Genet. 101 (1): 43–6.
  38. Gottlieb B, Pinsky L, Beitel LK, Trifiro M (December 1999). Androgen insensitivity. Am. J. Med. Genet. 89 (4): 210–7.
  39. Edwards A, Hammond HA, Jin L, Caskey CT, Chakraborty R (February 1992). Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 12 (2): 241–53.
  40. Yeh SH, Chiu CM, Chen CL, Lu SF, Hsu HC, Chen DS, Chen PJ (April 2007). Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int. J. Cancer 120 (8): 1610–7.
  41. Casella R, Maduro MR, Misfud A, Lipshultz LI, Yong EL, Lamb DJ (January 2003). Androgen receptor gene polyglutamine length is associated with testicular histology in infertile patients. J. Urol. 169 (1): 224–7.
  42. Dowsing AT, Yong EL, Clark M, McLachlan RI, de Kretser DM, Trounson AO (August 1999). Linkage between male infertility and trinucleotide repeat expansion in the androgen-receptor gene. Lancet 354 (9179): 640–3.
  43. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong EL (November 1997). Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J. Clin. Endocrinol. Metab. 82 (11): 3777–82.
  44. Lim HN, Chen H, McBride S, Dunning AM, Nixon RM, Hughes IA, Hawkins JR (March 2000). Longer polyglutamine tracts in the androgen receptor are associated with moderate to severe undermasculinized genitalia in XY males. Hum. Mol. Genet. 9 (5): 829–34.
  45. 45.0 45.1 Hiort O, Holterhus PM, Horter T, Schulze W, Kremke B, Bals-Pratsch M, Sinnecker GH, Kruse K (August 2000). Significance of mutations in the androgen receptor gene in males with idiopathic infertility. J. Clin. Endocrinol. Metab. 85 (8): 2810–5.
  46. Kukuvitis A, Georgiou I, Bouba I, Tsirka A, Giannouli CH, Yapijakis C, Tarlatzis B, Bontis J, Lolis D, Sofikitis N, Papadimas J (June 2002). Association of oestrogen receptor alpha polymorphisms and androgen receptor CAG trinucleotide repeats with male infertility: a study in 109 Greek infertile men. Int. J. Androl. 25 (3): 149–52.
  47. von Eckardstein S, Syska A, Gromoll J, Kamischke A, Simoni M, Nieschlag E (June 2001). Inverse correlation between sperm concentration and number of androgen receptor CAG repeats in normal men. J. Clin. Endocrinol. Metab. 86 (6): 2585–90.
  48. Rajpert-De Meyts E, Leffers H, Petersen JH, Andersen AG, Carlsen E, Jørgensen N, Skakkebaek NE (January 2002). CAG repeat length in androgen-receptor gene and reproductive variables in fertile and infertile men. Lancet 359 (9300): 44–6.
  49. Hiort O, Horter T, Schulze W, Kremke B, Sinnecker GH (November 1999). Male infertility and increased risk of diseases in future generations. Lancet 354 (9193): 1907–8.
  50. Muroya K, Sasagawa I, Suzuki Y, Nakada T, Ishii T, Ogata T (May 2001). Hypospadias and the androgen receptor gene: mutation screening and CAG repeat length analysis. Mol. Hum. Reprod. 7 (5): 409–13.
  51. Radpour R, Rezaee M, Tavasoly A, Solati S, Saleki A (2007). Association of long polyglycine tracts (GGN repeats) in exon 1 of the androgen receptor gene with cryptorchidism and penile hypospadias in Iranian patients. J. Androl. 28 (1): 164–9.
  52. Aschim EL, Nordenskjöld A, Giwercman A, Lundin KB, Ruhayel Y, Haugen TB, Grotmol T, Giwercman YL (October 2004). Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. J. Clin. Endocrinol. Metab. 89 (10): 5105–9.
  53. Rajender S, Rajani V, Gupta NJ, Chakravarty B, Singh L, Thangaraj K (2006). No association of androgen receptor GGN repeat length polymorphism with infertility in Indian men. J. Androl. 27 (6): 785–9.
  54. 54.0 54.1 Yong EL, Ng SC, Roy AC, Yun G, Ratnam SS (September 1994). Pregnancy after hormonal correction of severe spermatogenic defect due to mutation in androgen receptor gene. Lancet 344 (8925): 826–7.
  55. Hughes IA, Houk C, Ahmed SF, Lee PA (July 2006). Consensus statement on management of intersex disorders. Arch. Dis. Child. 91 (7): 554–63.
  56. 56.0 56.1 Weidemann W, Peters B, Romalo G, Spindler KD, Schweikert HU (April 1998). Response to androgen treatment in a patient with partial androgen insensitivity and a mutation in the deoxyribonucleic acid-binding domain of the androgen receptor. J. Clin. Endocrinol. Metab. 83 (4): 1173–6.
  57. Tincello DG, Saunders PT, Hodgins MB, Simpson NB, Edwards CR, Hargreaves TB, Wu FC (April 1997). Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome. Clin. Endocrinol. (Oxf) 46 (4): 497–506.
  58. Nieschlag E (September 2006). Testosterone treatment comes of age: new options for hypogonadal men. Clin. Endocrinol. (Oxf) 65 (3): 275–81.

External linksEdit

Template:Transcription factor/coregulator deficiencies

This page uses Creative Commons Licensed content from Wikipedia (view authors).
Advertisement | Your ad here

Around Wikia's network

Random Wiki